WallStSmart

Abbott Laboratories (ABT)vsTaseko Mines Ltd (TGB)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 6607% more annual revenue ($45.13B vs $672.90M). ABT leads profitability with a 13.9% profit margin vs -4.5%. TGB appears more attractively valued with a PEG of 0.33. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

TGB

Hold

48

out of 100

Grade: D+

Growth: 6.7Profit: 3.0Value: 5.7Quality: 3.0
Piotroski: 2/9Altman Z: 0.54
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+0.6%)

Margin of Safety

+0.6%

Fair Value

$87.53

Current Price

$84.32

$3.21 discount

UndervaluedFair: $87.53Overvalued
TGBSignificantly Overvalued (-17.4%)

Margin of Safety

-17.4%

Fair Value

$7.11

Current Price

$7.49

$0.38 premium

UndervaluedFair: $7.11Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

TGB2 strengths · Avg: 10.0/10
PEG RatioValuation
0.3310/10

Growing faster than its price suggests

Revenue GrowthGrowth
45.3%10/10

Revenue surging 45.3% year-over-year

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

TGB4 concerns · Avg: 2.5/10
Debt/EquityHealth
1.583/10

Elevated debt levels

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-4.7%2/10

ROE of -4.7% — below average capital efficiency

EPS GrowthGrowth
-45.5%2/10

Earnings declined 45.5%

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : TGB

The strongest argument for TGB centers on PEG Ratio, Revenue Growth. Revenue growth of 45.3% demonstrates continued momentum. PEG of 0.33 suggests the stock is reasonably priced for its growth.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : TGB

The primary concerns for TGB are Debt/Equity, Piotroski F-Score, Return on Equity. Debt-to-equity of 1.58 is elevated, increasing financial risk.

Key Dynamics to Monitor

ABT profiles as a value stock while TGB is a hypergrowth play — different risk/reward profiles.

TGB carries more volatility with a beta of 2.02 — expect wider price swings.

TGB is growing revenue faster at 45.3% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 48/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

Taseko Mines Ltd

BASIC MATERIALS · COPPER · USA

Taseko Mines Limited, a mining company, acquires, develops and operates mineral properties. The company is headquartered in Vancouver, Canada.

Visit Website →

Want to dig deeper into these stocks?